Abstract
Accumulating evidences indicated that plasmacytoma variant translocation 1 (PVT1) plays vital roles in several cancers. However, the expression, functions, and clinical values of PVT1 in melanoma are still unknown. In this study we measured the expression of PVT1 in clinical tissues and serum samples and explored the diagnostic value of PVT1 for melanoma and the effects of PVT1 on melanoma cell proliferation, cell cycle, and migration. Our results, combined with publicly available PVT1 expression data, revealed that PVT1 is upregulated in melanoma tissues compared with nonneoplastic nevi tissues. Serum PVT1 level is significantly increased in melanoma patients compared with age and gender-matched nonmelanoma controls with melanocytic nevus. Receiver operating characteristic curve analyses revealed that serum PVT1 level could sensitively discriminate melanoma patients from controls. Furthermore, serum PVT1 level indicted melanoma dynamics. Functional experiments showed that overexpression of PVT1 promotes melanoma cells proliferation, cell cycle progression, and migration, while depletion of PVT1 significantly inhibits melanoma cells proliferation, cell cycle progression, and migration. Collectively, our results indicate that PVT1 functions as an oncogene in melanoma and could be a potential diagnostic biomarker and therapeutic target for melanoma.
Highlights
The incidence of melanoma is increasing quickly worldwide for the past 30 years and will continue to increase in the future [1]
We explored the functions of plasmacytoma variant translocation 1 (PVT1) in melanoma cell proliferation, cell cycle, and migration
The results showed that serum PVT1 expression is significantly reduced in postoperational melanoma patients (Figure 3(a))
Summary
The incidence of melanoma is increasing quickly worldwide for the past 30 years and will continue to increase in the future [1]. It is predicted that melanoma will be an enormous public healthy and economic burden for human [2]. There are 160,000 estimated new cases of melanoma and 48,000 estimated deaths from melanoma in the world every year [3]. Early stage melanoma could be cured by surgery section, the treatment for later stage melanoma is still difficult and less efficient [4]. It is critical to diagnose melanoma at early stage and develop more efficient molecular targeted therapies for melanoma [5]. There are still no broadly used serum biomarkers for melanoma early diagnosis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
